First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

Secarna Pharmaceuticals’ strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases

Secarna Pharmaceuticals has initiated a transnational scientific consortium to identify new biomarkers for personalized cancer immunotherapy with ASOs

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus™-based ASOs to effectively treat diabetic kidney disease

Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director